Johnson Daniel Y, Liu Michael, Bartlett Victoria L, Zheng ZhaoNian, Oseran Andrew S, Wadhera Rishi K
Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.
Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
J Am Coll Cardiol. 2025 Jul 29;86(4):259-267. doi: 10.1016/j.jacc.2025.05.037. Epub 2025 Jun 9.
Private equity firms have rapidly acquired U.S. hospitals and increasingly invested in cardiology over the past decade. However, little is known about how private equity acquisition of hospitals affects care and outcomes for patients with heart failure.
The purpose of this study was to evaluate whether clinical care and outcomes changed for patients with heart failure after the acquisition of U.S. hospitals by private equity firms compared with matched control hospitals.
This study identified U.S. hospitals acquired by private equity firms and matched control hospitals from 2012 through 2019. A quasiexperimental difference-in-differences analysis was used to evaluate changes in clinical outcomes, the case mix of admissions and transfers, as well as cardiac procedure utilization among Medicare fee-for-service beneficiaries aged 65 years or older with heart failure.
There were 41 private equity-acquired hospitals and 192 matched control hospitals. After private equity acquisition of hospitals, there was no change in 30-day mortality rates (difference-in-differences [DiD] +0.7 percentage points [95% CI: -0.4 to 1.8]) or 30-day hospital revisit rates (DiD -0.2 percentage points [95% CI: -0.9 to 0.5]), despite a significant decrease in the clinical risk of patients with heart failure when compared with those at matched control (nonacquired) hospitals. Overall hospital transfer rates did not change, but Black patients were significantly more likely to be transferred out to another site after private equity acquisition (DiD +7.1 percentage points [95% CI: 0.7-13.4]), a change not observed across other racial groups. In addition, there was a significant increase in cardiac catheterization rates (DiD estimate, +0.7 percentage points [95% CI: 0.1-1.2]) among heart failure patients at private equity-acquired vs control hospitals.
These findings suggest that private equity acquisitions of U.S. hospitals do not improve outcomes among older adults with heart failure, despite a decrease in the clinical risk of patients admitted to these sites.
在过去十年中,私募股权公司迅速收购了美国医院,并越来越多地投资于心脏病学领域。然而,对于私募股权公司收购医院如何影响心力衰竭患者的护理和治疗结果,人们知之甚少。
本研究的目的是评估与匹配的对照医院相比,私募股权公司收购美国医院后,心力衰竭患者的临床护理和治疗结果是否发生了变化。
本研究确定了2012年至2019年被私募股权公司收购的美国医院和匹配的对照医院。采用准实验性差异分析来评估临床结果的变化、入院和转院的病例组合,以及65岁及以上患有心力衰竭的医疗保险按服务收费受益人的心脏手术利用率。
有41家被私募股权收购的医院和192家匹配的对照医院。私募股权公司收购医院后,30天死亡率(差异分析[DiD]+0.7个百分点[95%置信区间:-0.4至1.8])或30天医院再入院率(DiD -0.2个百分点[95%置信区间:-0.9至0.5])没有变化,尽管与匹配的对照(未收购)医院的患者相比,心力衰竭患者的临床风险显著降低。总体医院转院率没有变化,但黑人患者在私募股权收购后被转至其他医院的可能性显著更高(DiD +7.1个百分点[95%置信区间:0.7-13.4]),其他种族群体未观察到这种变化。此外,与对照医院相比,私募股权收购的医院中,心力衰竭患者的心脏导管插入率显著增加(DiD估计值,+0.7个百分点[95%置信区间:0.1-1.2])。
这些发现表明,私募股权公司收购美国医院并没有改善老年心力衰竭患者的治疗结果,尽管入住这些医院的患者临床风险有所降低。